'Junk DNA' plays active role in cancer progression, researchers find

Scientists at The University of Nottingham have found that a genetic rogue element produced by sequences until recently considered 'junk DNA' could promote cancer progression.

The researchers, led by Dr Cristina Tufarelli, in the School of Graduate Entry Medicine and Health Sciences, discovered that the presence of this faulty genetic element—known as chimeric transcript LCT13—is associated with the switching off of a known tumour suppressor gene (known as TFPI-2) whose expression is required to prevent and metastasis.

Their findings, published online this month in the journal Nucleic Acid Research, suggest that LCT13 may be involved in switching off TFPI-2.

This faulty was previously identified by Dr Tufarelli's team as part of a group of chimeric transcripts which are produced by frequently regarded as 'junk DNA' called LINE-1 (L1).

The work reported now expands on the previous observation as it indicates that in addition to acting as potential diagnostic tools these rogue elements can play an active role in cancer.

Dr Tufarelli said: "This study has identified a novel way in which '' can interfere with the normal functioning of a cell. The next step will be to understand how these elements become switched on. This information will be important in the design of treatments aimed to prevent activation of these elements and ."

The work was initiated through funding by Cancer Research UK, the Royal Society, MRC and Breakthrough Breast Cancer.

A copy of the paper, Expression of a Large LINE-1 Driven Antisense RNA is Linked to Epigenetic Silencing of the Metastasis Suppressor Gene TFPI-2 in Cancer, is available to view online on the website for the journal Nucleic Acid Research.

Related Stories

'Junk DNA' could spotlight breast and bowel cancer

Jan 05, 2010

Scientists at The University of Nottingham have found that a group of genetic rogue elements, produced by DNA sequences commonly known as 'junk DNA', could help diagnose breast and bowel cancer. Their research, funded by ...

RNA promotes metastasis in lung cancer

Feb 05, 2013

The vast majority – approximately 80 percent – of our DNA does not code for proteins, yet it gets transcribed into RNA. These RNA molecules are called non-coding and fulfill multiple tasks in the cell. Alongside a well-studied ...

Study finds new drug target for metastatic breast cancer

Apr 11, 2013

Research led by Dr. Suresh Alahari, Professor of Biochemistry and Molecular Biology at LSU Health Sciences Center New Orleans, is the first to report that two specific tumor suppressor genes work in concert to inhibit the ...

Recommended for you

Survival hope for melanoma patients thanks to new vaccine

1 hour ago

(Medical Xpress)—University of Adelaide researchers have discovered that a new trial vaccine offers the most promising treatment to date for melanoma that has spread, with increased patient survival rates and improved ability ...

New clinical trial launched for advance lung cancer

4 hours ago

Cancer Research UK is partnering with pharmaceutical companies AstraZeneca and Pfizer to create a pioneering clinical trial for patients with advanced lung cancer – marking a new era of research into personalised medicines ...

User comments